Difluprednate for reducing the adverse effects of ocular inflammation

JP2024501425A5Inactive Publication Date: 2024-11-22SUN PHARMA ADVANCED RESEARCH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023533743
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-03
Filing Date
2021-12-03
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

The present invention provides an aqueous solution comprising difluprednate as the only active ingredient, wherein the aqueous solution comprises 0.02-0.04% w / v difluprednate and an aqueous vehicle, wherein the aqueous solution is oil-free, and wherein the aqueous solution is administered to a subject twice daily for 7 to 21 days, and a method of using the aqueous solution to reduce adverse effects associated with an ocular inflammatory disorder in a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to a method of reducing the adverse effects of an ocular inflammatory disorder in a subject in need thereof, the method comprising administering to the eye of the subject an aqueous ophthalmic solution of difluprednate. [Background technology]

[0002] Difluprednate is an anti-inflammatory corticosteroid drug represented by formula I below:

[0003] [ka]

[0004] Difluprednate, a steroid drug, is substantially insoluble in aqueous vehicles. The current marketed formulation of difluprednate is an emulsion form of difluprednate approved and marketed in the United States under the trade name DUREZOL® (Novartis, East Hanover, NJ). DUREZOL® is an ophthalmic emulsion formulation of difluprednate containing 0.05% w / v difluprednate emulsified between castor oil and water. It is not a clear aqueous solution. U.S. Patent No. 6,114,319 (hereinafter the '319 patent), which is listed in the "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations" for the DUREZOL® product, describes an emulsion formulation of difluprednate containing oil and an emulsifier. DUREZOL® emulsion formulations are indicated for the treatment of inflammation and pain associated with ophthalmic surgery and endogenous anterior uveitis when administered four times per day. Because the emulsion needs to be injected four times per day, there is a high likelihood of patient noncompliance and missed doses. Prior art formulations of difluprednate do not provide long-term action. Furthermore, the most common adverse reactions in subjects exposed to DUREZOL® (occurring in 5-10% of subjects) have been reported and are listed in the approved labeling for DUREZOL®, including blurred vision, ocular irritation, ocular pain, headache, increased TOP, iritis, limbal and conjunctival hyperemia, and punctate keratitis. Thus, there is a need for a formulation of difluprednate that is devoid of these side effects and addresses the existing shortcomings. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] U.S. Patent No. 6,114,319 Summary of the Invention

[0006] The present disclosure provides an aqueous solution comprising a therapeutically effective concentration of difluprednate, a crystal growth inhibitor, and a pharma- ceutically acceptable amount of a solubilizing agent in an aqueous vehicle comprising a mixture of i) a quaternary ammonium compound and ii) a polyethoxylated castor oil, wherein the crystal growth inhibitor is polyvinyl alcohol or a derivative thereof.

[0007] In another aspect, the present disclosure provides a method of treating an ocular inflammatory disorder, the method comprising administering to an eye of a person in need thereof an aqueous solution comprising difluprednate as a sole active ingredient at a concentration of about 0.02-0.04% weight / volume, wherein the solution is oil-free, and wherein the solution is administered twice daily, and wherein the subject is not receiving rescue treatment, and wherein after treatment, the subject has an anterior chamber cell (ACC) grade of 0 and a visual analog scale (VAS) pain score of 0 after ocular surgery.

[0008] In some embodiments, the disclosure provides a method of reducing adverse effects associated with an ocular inflammatory disorder in a subject in need thereof, the method comprising administering to the eye of the subject an aqueous solution comprising difluprednate as a sole active ingredient, wherein the aqueous solution comprises 0.02-0.04% w / v difluprednate and an aqueous vehicle, wherein the aqueous solution is oil-free, and wherein the aqueous solution is administered to the subject twice daily for 7-21 days.

[0009] In some embodiments, the disclosure provides a method of reducing adverse effects associated with an ocular inflammatory disorder in a population of subjects in need of such reduction, the method comprising administering to the eyes of the population of subjects an aqueous solution comprising difluprednate as the only active ingredient, wherein the aqueous solution comprises 0.02-0.04% w / v difluprednate and an aqueous vehicle, wherein the aqueous solution is oil-free, and wherein the aqueous solution is administered to the population of subjects twice daily for 7-21 days. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] An "aqueous solution" as referred to herein is a solution of difluprednate in an aqueous vehicle, where the difluprednate is in solubilized form and not in particulate form, either microparticles or nanoparticles or micellar form.

[0011] The term "crystal growth inhibitor" as used herein refers to an additional excipient that prevents difluprednate from precipitating or crystallizing from the aqueous vehicle. Screening for the inhibitory effect of difluprednate crystal growth can be performed by physical observation as well as by determining the clarity of the aqueous solution immediately after formulation or upon storage. The solution exhibits a transmittance of greater than 90%, e.g., greater than 95%. When light is transmitted through an ophthalmic solution, the percentage of incident light that is transmitted through the solution is referred to as the "percent transmittance." Generally, transmittance is determined at a wavelength of about 650 nm, although any other suitable wavelength may be selected to determine the clarity of the solution. The aqueous solutions of the present disclosure exhibit a transmittance of greater than 90%, e.g., greater than 95% or even greater than 99%. The aqueous solutions remain clear and free of particles, crystals or precipitates after extended storage at temperatures between 2°C and 30°C for periods of 6 months or more.

[0012] The aqueous solutions of the present disclosure do not include oils. The term "oil" as used herein refers to oils that are hydrophobic compounds. Examples of "oils" include, but are not limited to, triglycerides such as castor oil, peanut oil, peanut oil, mineral oil, etc. The term "oil" does not include amphiphilic compounds or surfactants obtained by derivatizing oils with hydrophilic entities, such as polyethoxylated castor oil.

[0013] The aqueous ophthalmic solution of the present disclosure comprises a therapeutically effective concentration of difluprednate, a crystal growth inhibitor, and a solubilizing agent in a pharma- ceutically acceptable amount of an aqueous vehicle comprising a mixture of i) a quaternary ammonium compound and ii) a polyethoxylated castor oil, where the crystal growth inhibitor is polyvinyl alcohol or a derivative thereof.

[0014] The aqueous ophthalmic solution used in accordance with the present disclosure contains difluprednate as the only therapeutically active ingredient. The term "difluprednate" as used herein includes prodrugs of difluprednate in which the hydroxyl group in difluprednate is converted to an unstable ester or amide. In one embodiment, the aqueous ophthalmic solution according to the present disclosure does not contain povidone-iodine or other active ingredients, and always contains only one active ingredient. The concentration of difluprednate (% weight / volume) is expressed on a difluprednate basis. It is present in a concentration ranging from about 0.005 to 0.07% weight / volume, such as about 0.02 to 0.045% weight / volume, such as 0.025, 0.03, 0.035, 0.036, 0.037, 0.038, 0.039, 0.04, 0.041, 0.042, or 0.043% weight / volume, or about 0.02 to 0.04% weight / volume.

[0015] The present disclosure's aqueous ophthalmic solution comprises a solubilizer that is a mixture of quaternary ammonium compounds and polyethoxylated castor oil.When using individual solubilizers, i.e., quaternary ammonium compounds alone or polyethoxylated castor oil alone, it is found that difluprednate is not successfully solubilized, and difluprednate precipitates from solution immediately or during storage.Surprisingly, when using the mixture of these two categories of solubilizers, a clear aqueous solution is obtained, i.e., there is no precipitation of difluprednate during preparation or storage.

[0016] The quaternary ammonium compound is selected from, but not limited to, benzalkonium chloride, myristyl gamma picolinium chloride, benzethonium chloride, benzododecinium bromide, cetalkonium chloride, cetylpyridinium chloride, cetrimonium, tetraethylammonium bromide, polyhexamethylene biguanide, oleylamine, and the like. In some embodiments, the quaternary ammonium compound is selected from benzalkonium chloride and myristyl gamma picolinium chloride. The quaternary ammonium compound is used in the ophthalmic solution in an amount ranging from about 0.0002 to 0.1% weight / volume, for example, from about 0.002 to about 0.08% weight / volume, such as, for example, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, or 0.07% weight / volume. According to one particular embodiment, the quaternary ammonium compound is benzalkonium chloride and is present in the aqueous ophthalmic solution in an amount ranging from about 0.0002 to 0.08% weight / volume, such as from about 0.0002 to 0.05% weight / volume, or from about 0.005 to 0.05% weight / volume, such as from about 0.01 to 0.03% weight / volume.

[0017] The polyethoxylated castor oil used as a solubilizing agent according to the present disclosure is also known by other terms such as polyoxyl castor oil or polyoxyethylene castor oil. It is sold under various trade names such as Cremophor®, Acconon®, Arlatone®, Eumulgin®, Etocas®, Jeechem®, Hetoxide®, Nikkol®, and Croduret®. Polyethoxylated castor oil or polyoxyethylene castor oil derivatives that may be used in the aqueous ophthalmic solutions of the present disclosure are described in "Handbook of Pharmaceutical Excipients", fifth edition, 2006, pages 572-578. In some embodiments, the ophthalmic aqueous solution of the present disclosure comprises polyoxyl 35 castor oil commercially available under the trade name Cremophor® EL by BASF Corp., polyoxyl 40 castor oil commercially available under the trade name Croduret® 40 or Etocas® 40, polyoxyl 60 castor oil commercially available under the trade name Jeechem® CA-60, polyoxyl 15 castor oil commercially available under the trade name Jeechem® CA-15 or Acconon® CA-15. In some embodiments, the polyethoxylated castor oil is used in the ophthalmic aqueous solution of the present disclosure in a pharma- ceutically acceptable amount. In some embodiments, the pharma-ceutically acceptable amount of polyethoxylated castor oil ranges from about 1.0 to 10.0% weight / volume. In some embodiments, the polyethoxylated castor oil is present in the aqueous ophthalmic solution in an amount ranging from about 1.5-6.0% w / v, such as 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, or 5.5% weight / volume of the solution. According to one particular embodiment, the "polyethoxylated castor oil" is polyoxyl 35 castor oil and is present in the aqueous ophthalmic solution in a pharma- ceutically acceptable amount ranging from about 3.0-6.0% w / v.

[0018] The crystal growth inhibitor present in the aqueous solution is polyvinyl alcohol or its derivative. Without the presence of a crystal growth inhibitor, difluprednate does not remain in a solubilized form in the aqueous vehicle and precipitates upon standing / storage. Derivatives of polyvinyl alcohol include, but are not limited to, polyvinyl alcohol-polyethylene glycol graft copolymer (sold under the trade name Kollicoat®), poly(vinyl alcohol coethylene), polystyrene-polyvinyl alcohol graft copolymer, polyvinyl alcohol-polyvinyl pyrrolidone graft copolymer, polyvinyl alcohol-lactic acid graft copolymer, polyvinyl alcohol-carrageenan graft copolymer, polyvinyl alcohol-polyether graft copolymer, and the like, and mixtures thereof. In a particular embodiment, the crystal growth inhibitor is polyvinyl alcohol. In one embodiment, the crystal growth inhibitor is in the range of about 0.1 to 5.0% weight / volume of the solution, such as about 0.5 to 3.0% weight / volume, such as 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.2, 2.4, 2.5, 2.6, 2.7, 2.8, or 2.9% weight / volume. In another embodiment, the amount of crystal growth inhibitor is in the range of about 1 to about 2% weight / volume.

[0019] The aqueous solutions of the present disclosure may further include other conventional excipients such as surfactants, thickening agents, preservatives, chelating agents, co-solvents, buffers, and the like.

[0020] The surfactants used in the present disclosure include mixtures of nonionic, anionic, and cationic surfactants. Nonionic surfactants include alkyl ethers such as polyethoxylated castor oil, polyoxyethylene octyl ether, polyoxyethylene lauryl ether, polyoxyethylene stearyl ether, and polyoxyethylene oleyl ether; alkyl phenyl ethers such as polyoxyethylene octylphenyl ether and polyoxyethylene nonylphenyl ether; alkyl esters such as polyoxyethylene laurate, polyoxyethylene stearate, and polyoxyethylene oleate; polyoxyethylene lauryl amino ether, polyoxyethylene stearyl amino ether, polyoxyethylene oleyl amino ether, polyoxyethylene soybean amino ether, polyoxyethylene oleyl ... The surfactant is selected from alkylamines such as polyoxyethylene tallow amino ether and polyoxyethylene tallow amino ether; alkyl amides such as polyoxyethylene lauryl amide, polyoxyethylene stearic acid amide, and polyoxyethylene oleic acid amide; vegetable oil ethers such as polyoxyethylene rapeseed oil ether; alkanolamides such as lauric acid diethanolamide, stearic acid diethanolamide, and oleic acid diethanolamide; and sorbitan ester ethers such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monostearate, and polyoxyethylene sorbitan monooleate. In some embodiments, the surfactant is polyethoxylated castor oil. In one or more embodiments, the amount of nonionic surfactant ranges from about 1.5 to about 6.0% weight / volume.

[0021] The anionic surfactant is selected from acyl sarcosines or sarcosinates.

[0022] The acylated amino acids according to the present disclosure are N-acyl fatty acid derivatives of natural amino acids. They are generally anionic in nature and soluble in water. The acylated amino acids used in the ophthalmic solution are selected from the group consisting of, but not limited to, acyl sarcosine or sarcosinate, acyl glutamate, acyl glycinate, acyl aspartate, acyl taurate, acyl malonate or acyl amino malonate, salts thereof or mixtures thereof. In general, the salts include sodium salts, potassium salts, ammonium salts, amine salts, triethanolamine salts, etc.

[0023] Acyl sarcosines and their salts are represented by Formula II, shown below:

[0024] [ka] In the formula, R is C4 to C 21 is a fatty acid radical having carbon atoms, X represents a salt such as a sodium salt, a potassium salt, an ammonium salt, an amine salt, or a triethanolamine salt.

[0025] Non-limiting examples of acyl sarcosines include, but are not limited to, N-lauroyl sarcosine, N-oleoyl sarcosine, N-stearoyl sarcosine, N-myristoyl sarcosine, N-cocoyl sarcosine or salts thereof, such as sodium N-lauroyl sarcosine or sodium N-lauroyl sarcosine, potassium N-lauroyl sarcosine or potassium N-lauroyl sarcosine, sodium N-oleoyl sarcosinate, sodium N-stearoyl sarcosinate, sodium N-myristoyl sarcosine, sodium N-coil sarcosine, ammonium cocoyl sarcosine, ammonium lauroyl sarcosine, etc., or mixtures thereof.

[0026] Non-limiting examples of acyl glutamates include, but are not limited to, N-lauroyl glutamate, N-oleoyl glutamate, N-stearoyl glutamate, N-myristoyl glutamate or salts thereof, such as mono-sodium N-lauroyl glutamate, potassium N-lauroyl glutamate or mixtures thereof.

[0027] Non-limiting examples of N-acyl glycinates include, but are not limited to, N-lauroyl glycinate, N-oleoyl glycinate, N-stearoyl glycinate, N-myristoyl glycinate, or salts thereof.Non-limiting examples of N-acylaspartates include, but are not limited to, N-lauroyl aspartate, N-oleoyl aspartate, N-stearoyl aspartate, N-myristoyl aspartate, or salts thereof.Non-limiting examples of N-acyltaurates include, but are not limited to, N-lauroyl taurate, N-oleoyl taurate, N-stearoyl taurate, N-myristoyl taurate, N-methylacyltaurate, or salts thereof. Non-limiting examples of acyl aminomalonates include, but are not limited to, N-lauroyl aminomalonate, N-oleoyl aminomalonate, N-stearoyl aminomalonate, N-myristoyl aminomalonate, or salts thereof.

[0028] In some embodiments, the acylated amino acid is a sarcosine compound, i.e., N-acyl sarcosine or a salt thereof, such as N-lauroyl sarcosine or a salt thereof. In certain embodiments, the acylated amino acid is the sodium salt of N-lauroyl sarcosine, i.e., sodium N-lauroyl sarcosine or sodium N-lauroyl sarcosinate, represented by the compound of formula III below.

[0029] [ka]

[0030] In another embodiment, the acylated amino acid is the sodium salt of N-lauroyl glutamate, ie, monosodium N-lauroyl glutamate.

[0031] Other anionic surfactants that may be used include, but are not limited to, lactylates, alkylbenzenesulfonates, alkyl sulfates, polyoxyethylene alkyl sulfates, aliphatic α-sulfomethyl esters, α-olefin sulfonic acids, sodium lauryl sulfate, sodium dioctyl sulfosuccinate, n-acylated polypeptides sodium n-lauryl sarcosinate and triethanolamine salts of triethanolammonium lauryl sulfate, and sodium naphthylenesulfonate.

[0032] In some embodiments, the anionic surfactant is N-lauroyl sarcosine. In one or more embodiments, the amount of the anionic surfactant is in the range of about 0.01-0.1% w / v, such as about 0.03-0.06% w / v, such as 0.03, 0.035, 0.04, 0.045, 0.05, 0.055, 0.06% w / v.

[0033] The cationic surfactant is selected from primary, secondary and tertiary highly cationizable and quaternary amines. In more specific embodiments, the cationic surfactant is selected from oleylamine, stearylamine, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, cetyltyridinium bromide, dodecyltrimethylammonium bromide, trimethyltetradecylammonium bromide, hexadecyltrimethylammonium bromide and poloxamines (e.g., Tetronic™) or mixtures thereof. In some embodiments, the cationic surfactant is benzalkonium chloride. In one or more embodiments, the amount of cationic surfactant ranges from about 0.002 to about 0.3% weight / volume.

[0034] In some embodiments, the surfactant system comprises a mixture of polyethoxylated castor oil, N-lauroyl sarcosine and benzalkonium chloride. A mixture of non-ionic, cationic and anionic surfactant forms can be mixed in a micellar system in which the water-insoluble difluprednate is solubilized.

[0035] The absence of either quaternary ammonium compounds (benzalkonium chloride) or compounds such as polyethoxylated castor oil (Cremophor®) or acylated amino (N-lauroyl sarcosine) may alter the functional properties such as solubilization, stabilization and preservative efficacy of the formulation.

[0036] Viscosifying agents that can be used include, but are not limited to, carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxyethylstarch, dextran, xanthan gum, sodium alginate, starch, sodium hyaluronate, carbopol, polyvinylpyrrolidone, and the like, or mixtures thereof. In some embodiments, the viscosity increasing agent is carboxymethylcellulose. Suitably, in some embodiments, the aqueous solution does not contain a viscosity increasing agent such as polycarbophil and chitosan having a high molecular weight. The viscosity of the aqueous solution according to the present disclosure generally ranges from about 1 cps to 2000 cps, such as from about 2 cps to 1000 cps, from about 1 cps to 300 cps, or from about 2 cps to 200 cps. In some embodiments, the viscosity of the ophthalmic aqueous solution is from about 2 cps to 30 cps. In one embodiment, the present disclosure provides an ophthalmic aqueous solution comprising a therapeutically effective amount of difluprednate as the sole active ingredient and having a viscosity between 2 cps and 200 cps, the aqueous solution being effective for treating inflammatory disorders of the eye when administered twice daily.

[0037] The aqueous ophthalmic solution may further contain one or more preservatives, especially when the dosage form is a multiple dose rather than a single dose. Preservatives that may be used include, but are not limited to, benzyl alcohol, cetrimide, chlorhexidine, chlorobutanol, mercurial preservatives such as phenylmercuric nitrate, phenylmercuric acetate, thimerosal, phenylethyl alcohol, Polyquad®, stabilized oxy-chloro complexes, stabilized peroxides and perborates, and the like. Safer preservative systems and preservative efficacy enhancers, such as disodium edetate, N-lauroyl sarcosine or its sodium salt, boric acid, borates, biguanides, such as polyhexamethylene biguanide, polyoxyalkylenediamine biguanide or its water-soluble salts, 1,1'-hexamethylene-bis-{5-(4-chlorophenyl)-biguanide}; 1,1'-hexamethylene-bis-{5-(4-fluorophenyl)-biguanide}; (N,N"-bis(2 -ethylhexyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimideamine; parabens (e.g., methyl-propyl, isopropyl and butyl-paraben), pyruvate, stabilized oxychloro compounds, sorbic acid / potassium sorbate, metal ions, peroxides, amino acids such as arginine, tromethamine and mixtures thereof. According to another embodiment of the present disclosure, the aqueous ophthalmic solution may be self-preserving.

[0038] In one embodiment, the ophthalmic aqueous solution employs a preservative selected from biguanides, boric acid, N-lauroyl sarcosine or mixtures thereof. In one embodiment, the ophthalmic aqueous solution comprises polyhexamethylene biguanide in an amount ranging from about 0.001-0.04% w / v, such as about 0.002-0.02% w / v, or such as 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01 or 0.02% w / v. In one embodiment, the ophthalmic aqueous solution comprises boric acid in an amount ranging from about 0.05-1.5% w / v, such as about 0.1-1.0% w / v, such as 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9% w / v, or 0.4-0.7% w / v. In one embodiment, the ophthalmic aqueous solution comprises N-lauroyl sarcosine in an amount ranging from about 0.001-0.5% w / v, such as 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 009, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4 or 0.45% w / v, such as about 0.01-0.1% w / v or 0.02-0.05% w / v. In one particular embodiment, the ophthalmic aqueous solution comprises a mixture of polyhexamethylene biguanide, boric acid and N-lauroyl sarcosine as preservatives. In one specific embodiment, when benzalkonium chloride is used alone, it is found that the solution is not effectively preserved, as shown by the results of the preservative efficacy test.When a biguanide is added to the solution, it is found that the solution is effectively preserved, i.e., the solution passes the preservative efficacy test specified in the European Pharmacopoeia.

[0039] Chelating agents that may be used include, but are not limited to, edetate disodium, ethylenediaminetetraacetic acid, edetic acid, edetate disodium dihydrate, diethylenetriaminepentaacetic acid, etc. A preferred chelating agent is ethylenediaminetriacetic acid or edetate disodium. In one embodiment, the aqueous ophthalmic solution comprises edetate disodium in an amount ranging from about 0.001-0.5% w / v, such as 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4 or 0.45% w / v, such as in an amount of about 0.01-0.1% w / v, or in an amount of 0.03-0.07% w / v.

[0040] The pH adjusting and / or buffering agents that may be used are selected from, but are not limited to, acetic acid, sodium acetate, tartaric acid, sodium tartrate, citric acid, sodium citrate, hydrochloric acid, sodium hydroxide or mixtures thereof. The osmolality / tonicity adjusting agents that may be used include, but are not limited to, sodium chloride, potassium chloride, sodium bromide, calcium chloride, mannitol, glycerol, sorbitol, propylene glycol, dextrose, sucrose, mannose, etc. and mixtures thereof. These solutions are characterized by an osmolality of 250-375 mOsm / kg, or 270-350 mOsm / kg, for example 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340 or 345 mOsm / kg. The osmolality of the solution is adjusted by the addition of an osmolality / tonicity adjusting agent.

[0041] Co-solvents that can be used include, but are not limited to, glycerol or glycerin, propylene glycol, ethylene glycol, polyethylene glycol, glycofurol, etc. The co-solvent, e.g., glycerol, may be present in the aqueous ophthalmic solutions of the present disclosure in an amount ranging from about 0.5% w / v to about 5.0% w / v, e.g., 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, or 4.5% w / v of the solution, e.g., from about 1.0% w / v to about 3.0% w / v.

[0042] Representative aqueous solutions of the present disclosure include the following compositions:

[0043] [Table 1]

[0044] According to various embodiments, an aqueous ophthalmic solution according to the present disclosure comprises the following composition:

[0045] [Table 2]

[0046] According to various embodiments, an aqueous ophthalmic solution according to the present disclosure comprises the following composition:

[0047] [Table 3]

[0048] According to various embodiments, an aqueous ophthalmic solution according to the present disclosure comprises the following composition:

[0049] [Table 4]

[0050] The first aqueous ophthalmic solution according to various embodiments comprises the following composition:

[0051] [Table 5]

[0052] The second aqueous ophthalmic solution according to various embodiments comprises the following composition:

[0053] [Table 6]

[0054] In another aspect, the present disclosure provides a method for treating an ocular inflammatory disorder, the method comprising administering to the eye of a subject in need thereof an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02-0.04% weight / volume in an aqueous vehicle, wherein the solution does not contain oil, and wherein the solution is administered twice daily, and wherein the subject is not receiving rescue treatment, and wherein after treatment, the subject had an anterior chamber cytology (ACC) grade of 0 and a visual analog scale (VAS) pain score of 0 after ocular surgery.

[0055] The ocular inflammatory disorder can be one or more of pain and inflammation associated with ocular surgery and uveitis. In certain aspects, the present disclosure provides a method of treating pain and inflammation associated with ocular surgery, the method comprising administering twice daily to the eye of a person in need thereof, an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02-0.04% weight / volume in an aqueous vehicle, wherein the solution is oil-free.

[0056] In particular, the disclosure provides a method of treating pain and inflammation associated with ocular surgery, the method comprising administering twice daily to the eye of a person in need thereof an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.04% weight / volume in an aqueous vehicle, wherein the solution is oil-free, and wherein the subject did not receive rescue treatment, and wherein following treatment, the subject had an anterior chamber cell (ACC) grade of 0 and a visual analog scale (VAS) pain score of 0 after ocular surgery.

[0057] Accordingly, some embodiments of the present disclosure provide a method of achieving anterior chamber cells (ACC) grade 0 in a subject in need thereof, the method comprising administering to the eye of the subject an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02-0.04% weight / volume in an aqueous vehicle, wherein the solution is oil-free, wherein the solution is administered twice daily for 7-21 days, and wherein the subject is not receiving rescue therapy. In certain embodiments, the subject in need thereof has undergone ocular surgery.

[0058] In another embodiment of the disclosure, there is provided a method of achieving a pain score of 0 on a visual analog scale (VAS) in a subject in need thereof, the method comprising administering to an eye of the subject an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02-0.04% weight / volume in an aqueous vehicle, wherein the solution is oil-free, wherein the solution is administered twice daily for 7-21 days, and wherein the subject is not receiving rescue therapy. In certain embodiments, the subject in need thereof has undergone ophthalmic surgery.

[0059] In certain embodiments, the present disclosure provides a method of treating pain and inflammation associated with cataract surgery, the method comprising administering twice daily to the eye of a person in need thereof an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.04% weight / volume in an aqueous vehicle, wherein the solution is oil-free, and wherein the subject did not receive rescue treatment, and wherein following treatment, the subject had an anterior chamber cell (ACC) grade of 0 and a visual analog scale (VAS) pain score of 0 after ocular surgery.

[0060] Some embodiments of the present disclosure include a method of reducing inflammation in the anterior chamber of an eye, comprising administering to an eye of a subject having undergone ophthalmic surgery an aqueous solution comprising difluprednate as a sole active ingredient at a concentration of 0.02-0.04% weight / volume in an aqueous vehicle, wherein the solution is oil-free, wherein the solution is administered twice daily, and wherein the subject does not receive rescue treatment, and wherein following treatment, the subject has a post-ophthalmic surgery anterior chamber cytology (ACC) grade of 0 and a visual analog scale (VAS) pain score of 0 15 days after administration. In certain aspects, the ophthalmic surgery is cataract surgery.

[0061] Another embodiment of the present disclosure is a method of treating an ocular inflammatory disorder, the method comprising administering to an eye of a patient in need thereof an aqueous solution comprising difluprednate as a sole active ingredient at a concentration of 0.02-0.04% w / v in an aqueous vehicle, wherein the solution is oil-free, wherein the solution is administered twice daily for 14 days, and wherein the patient is not receiving rescue treatment, and following treatment, the patient has an anterior chamber cell grade of 0. In certain aspects, the ocular inflammatory disorder is pain and inflammation associated with ocular surgery, and may be particularly associated with cataract surgery. In other aspects, the difluprednate is present at a concentration of 0.04% weight / volume. In yet other aspects, the method results in a pain score of 0 on a visual analog scale 15 days after ocular surgery, and the pain score on a visual analog scale may be assessed based on a scoring of ocular pain and discomfort from 0 to 100.

[0062] Another aspect of the disclosure relates to an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02-0.04% weight / volume in an aqueous vehicle for use in reducing inflammation in the anterior chamber of the eye in a subject who has had ophthalmic surgery, wherein the solution is oil-free, wherein the solution is administered twice daily, wherein the subject has not received rescue treatment, and wherein following treatment, the subject has a post-ophthalmic surgery anterior chamber cell (ACC) grade of 0 and a visual analog scale (VAS) pain score of 0 15 days after administration. In certain aspects, the ocular inflammatory disorder is pain and inflammation associated with ophthalmic surgery, and may be particularly associated with cataract surgery.

[0063] Yet another embodiment of the present disclosure relates to an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02-0.04% weight / volume in an aqueous vehicle for use in achieving anterior chamber cytology (ACC) grade 0 in a subject in need thereof, wherein the solution is oil-free, wherein the solution is administered twice daily for 7-21 days, and wherein the subject is not receiving rescue therapy. In certain embodiments, the ocular inflammatory disorder is pain and inflammation associated with ophthalmic surgery, and may be particularly associated with cataract surgery.

[0064] Another aspect of the disclosure relates to an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02-0.04% weight / volume in an aqueous vehicle for use in achieving a pain score of 0 on a visual analog scale (VAS) in a subject in need thereof, wherein the solution is oil-free, wherein the solution is administered twice daily for 7-21 days, and wherein the subject is not receiving rescue therapy. In certain aspects, the ocular inflammatory disorder is pain and inflammation associated with ophthalmic surgery, and may be particularly associated with cataract surgery.

[0065] In yet another aspect, the disclosure relates to an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02-0.04% w / v in an aqueous vehicle for use in treating ocular inflammatory disorders, wherein the solution is oil-free, wherein the solution is administered twice daily for 14 days, and wherein the patient does not receive rescue treatment, and wherein the patient has an anterior chamber cell grade of 0 after treatment. In certain aspects, the ocular inflammatory disorder is pain and inflammation associated with ocular surgery, and may be particularly associated with cataract surgery. In other aspects, the difluprednate is present at a concentration of 0.04% weight / volume. In still other aspects, the method results in a pain score of 0 on a visual analog scale 15 days after ocular surgery, and the pain score on a visual analog scale may be assessed based on a scoring of 0-100 for ocular pain and discomfort.

[0066] In one embodiment, the efficacy of treatment was measured by biomicroscopic measurements of anterior chamber cells (ACC) and measurement of the subject's pain level at each visit using a visual analog scale (VAS).

[0067] In some embodiments, the present disclosure provides a method of treating adverse effects of an inflammatory disorder in a population of subjects. As one of skill in the art will appreciate, in some embodiments, the effectiveness of the methods described herein on a single subject may vary. Applicants have found that the methods described herein, when used on a population of subjects, provide a measurable and consistent reduction in adverse effects associated with an inflammatory disorder. The present disclosure provides a method of reducing adverse effects associated with an ocular inflammatory disorder in a population of subjects in need of such reduction, comprising administering to the eye of the population of subjects an aqueous solution comprising difluprednate as the only active ingredient, wherein the aqueous solution comprises 0.02-0.04% w / v difluprednate and an aqueous vehicle, wherein the aqueous solution is oil-free, and wherein the aqueous solution is administered to the population of subjects twice daily for 7-21 days.

[0068] In some embodiments, the disclosed methods provided herein are for reducing adverse effects in a subject, e.g., a human subject, e.g., a female human subject or a male human subject. In some embodiments, the subject is an infant to 12 year old subject. In some embodiments, the subject is a 13 to 20 year old subject. In some embodiments, the subject is over 20 years old, e.g., 20 to 30 years old, 30 to 40 years old, 40 to 50 years old, or over 50 years old. In some embodiments, the population of subjects is a population of human subjects.

[0069] The aqueous solutions described herein may be administered twice daily for more than 7 days, more than 10 days, more than 12 days, more than 14 days, or more than 21 days. In some embodiments, the aqueous solution may be administered twice daily until adverse effects are alleviated. In some embodiments, the aqueous solution is administered for 12-16 days, or for only 14 days. The present disclosure demonstrates that administration twice daily for as little as 14 days may provide adequate relief of the adverse effects described herein. Thus, in some embodiments, the aqueous solution is administered twice daily for 14 days.

[0070] Various forms of administration are known in the art. The present disclosure provides that the current methods described herein result in the need for less administration of aqueous solutions, for example less frequent daily administration and shorter administration times. In some embodiments, administration is by topical application to the eye via eye drops. In some embodiments, administration is by injection into the eye.

[0071] Anterior chamber cells (ACC): Inflammation of the anterior segment of the eye causes a breakdown of the blood-aqueous barrier, resulting in an increase in aqueous humor cell count and protein concentration. Examination of the aqueous humor by slit-lamp biomicroscopy is the primary method used to assess the severity of anterior segment inflammation.

[0072] A slit lamp biomicroscope was used at 16x magnification with a 1x1mm oblique high intensity beam. The slit illumination was turned up to its highest intensity in all controls available for illumination. Focusing was done on the central cornea at the papillary axis, illumination was kept in the aqueous humor, and white cells were counted only at the focal plane. The focus was then moved to the central cornea and refocused in the aqueous humor to determine a second count. The two cell counts were summed and divided by two to determine the average final ACC count. This final cell count was converted to a grade as described below. If the averaged count is between two grades, the higher grade should be selected (e.g., if the two counts are 10 and 11, an average of 10.5 would fall into grade 2).

[0073] [Table 7]

[0074] Rescue treatment: Clinical trials in certain indications require the administration of rescue treatment if the subject does not respond adequately to the investigational treatment. However, applying additional treatments when necessary creates problems in the analysis and interpretation of the results of these studies, since the effect of the investigational treatment may be confounded by the additional treatment. However, it is still necessary to offer the subject the opportunity to receive established drug therapy, either alone or in combination with the investigational treatment, in case of insufficient response. This additional treatment is called rescue treatment.

[0075] Pain score: measured by a visual analog scale (VAS), consisting of a line with endpoints defining the extreme limits of "no pain" and "extreme pain" as possible. Subjects were asked to rate the sensation of the symptom in the eye from absent to extreme by moving the slide on the side of the scale to align it with a descriptive facial image. The scale was flipped to the other side and the relevant measurement recorded. The scale used 100 mm (10 cm) lines (0 = none; 100 = maximum).

[0076] Surprisingly, it has been found that the anti-inflammatory effect achieved by twice-daily administration of aqueous solutions having difluprednate as the sole active ingredient at concentrations of 0.03% weight / volume and 0.04% weight / volume is comparable to the anti-inflammatory effect obtained by four-times-daily administration of a prior art emulsion formulation available under the trade name Durezol® and having difluprednate at a concentration of 0.05% w / v. This is indeed surprising and unexpected since the prior art composition contains significant amounts of oil and further contains difluprednate at 0.05% weight / volume and is injected four times a day compared to the aqueous solution of the present disclosure having 0.04% w / v difluprednate, which is administered twice a day and the ophthalmic aqueous solution does not contain oil. This is even more surprising since difluprednate, being hydrophobic / oil soluble, would be expected to remain in the oil phase and therefore provide better efficacy in emulsion-type compositions compared to aqueous-based and most importantly oil-free compositions. The results found by the inventors are actually contrary to established hypotheses.

[0077] The present disclosure provides a clear, aqueous solution formulation of difluprednate for use in treating ocular inflammatory disorders that can be administered twice daily, with the added advantage that the solution form allows for the use of lower concentrations of difluprednate compared to existing prior art compositions or commercially available products.

[0078] The present disclosure provides a significant improvement in the method of treating ocular inflammatory disorders. Due to the transparent nature of the aqueous solution without suspended particles, the reduced frequency of administration, and the possibility of using reduced drug concentrations, and therefore improved ocular bioavailability, the method not only improves subject compliance, but also avoids adverse side effects such as blurred vision, irritation, and foreign body sensation upon instillation.

[0079] In one embodiment, the aqueous ophthalmic solution of difluprednate is useful for treating pain and inflammation associated with ophthalmic surgery by instillation twice daily into the affected eye of a subject. In another embodiment, the aqueous ophthalmic solution of the present disclosure is useful for treating pain and inflammation associated with cataract surgery by instillation twice daily into the affected eye of a subject.

[0080] Ocular inflammatory disorders that may be treated by administering an ophthalmic aqueous solution according to the present disclosure include, but are not limited to, pain and inflammation associated with ocular surgery, uveitis, acute anterior uveitis, intrinsic anterior uveitis, chronic uveitis, inflammation associated with ocular allergies, steroid-responsive inflammatory conditions of the eyelid and bulbar conjunctiva, the cornea and anterior portion of the eye such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, and herpes zoster keratitis. In some embodiments, the ophthalmic aqueous solution according to the present disclosure is useful in treating various forms of uveitis such as iritis or anterior uveitis, iridocyclitis and choroiditis, or posterior uveitis, acute anterior uveitis, and chorioretinitis, also known as chronic uveitis.

[0081] In one embodiment, the disclosure provides a method of treating pain and inflammation associated with ophthalmic surgery by instillation twice daily into the affected eye of a subject, comprising providing an aqueous ophthalmic solution comprising difluprednate at a concentration of about 0.02-0.04% weight / volume, wherein the solution is oil-free, and wherein the subject did not receive rescue treatment, and following treatment, the subject had an anterior chamber cell (ACC) grade of 0 and a visual analog scale (VAS) pain score of 0 after ophthalmic surgery.

[0082] In one embodiment, the disclosure provides a method of treating an ocular inflammatory disorder, the method comprising administering to an eye of a person in need thereof an aqueous solution comprising difluprednate as a sole active ingredient at a concentration of about 0.02-0.04% weight / volume, wherein the solution is oil-free, and wherein the solution is administered twice daily, further comprising a crystal growth inhibitor and a pharma- ceutically acceptable amount of a solubilizer comprising a mixture of a quaternary ammonium compound and polyethoxylated castor oil, the crystal growth inhibitor being polyvinylpyrrolidone or a derivative thereof, and the ocular inflammatory disorder being pain and inflammation associated with ocular surgery, wherein the subject did not receive rescue treatment, and following treatment, the subject had an anterior chamber cell (ACC) grade of 0 and a visual analog scale (VAS) pain score of 0 following ocular surgery.

[0083] The aqueous ophthalmic solution of the present disclosure enhances the ocular bioavailability of difluprednate, thus reducing its administration frequency. The aqueous solution of the present disclosure requires only two injections per day to achieve the desired therapeutic effect, whereas the commercially available difluprednate emulsion product DUREZOL® is instilled four times per day.

[0084] Thus, in one embodiment, the disclosure provides a method for enhancing the ocular bioavailability of difluprednate, the method comprising instilling an aqueous ophthalmic solution of difluprednate into the eye of a person in need thereof twice daily.

[0085] In one embodiment, the disclosure provides a method for enhancing the ocular bioavailability of difluprednate, the method comprising instilling twice daily into the eye of a person in need thereof, an aqueous ophthalmic solution comprising a therapeutically effective concentration of difluprednate, a crystal growth inhibitor, and a pharma- ceutically acceptable amount of a solubilizing agent comprising a mixture of a quaternary ammonium compound and polyethoxylated castor oil, in an aqueous vehicle.

[0086] The aqueous ophthalmic solution of the present disclosure improves the ocular bioavailability of difluprednate and reduces the dosing frequency to twice daily dosing versus the repeated four times daily dosing required for the commercially available emulsion product (DUREZOL®) to achieve the desired anti-inflammatory effect.

[0087] [Example] Although the present disclosure has been generally disclosed above, additional aspects will be further described and illustrated with reference to the following examples, however, the examples are presented merely to illustrate the present disclosure and should not be construed as limitations thereon.

[0088] [Examples 1 to 4] The examples describe aqueous ophthalmic solutions of difluprednate according to the present disclosure.

[0089] Table 1: Ophthalmic solutions of difluprednate [Table 8]

[0090] The required amount of benzalkonium chloride and difluprednate were taken in a container and polyoxyl 35 castor oil (Cremophor®) was added. Difluprednate was solubilized in the above mixture by intermittent sonication and vortexing to form a drug reconcentrate.

[0091] The required amount of polyvinyl alcohol was dissolved in water for injection at 70° C.-80° C. The other ingredients, namely boric acid, N-lauryl sarcosine, glycerin, disodium edetate, sodium acetate and acetic acid, were dissolved separately in a portion of the water for injection.

[0092] This phase was added to the polyvinyl alcohol solution with stirring. The drug pre-concentrate was added to the above mixture and dissolved by mixing with a magnetic stirrer to obtain solution (i). In the case of Example 4, following an additional step, the required amount of polyhexamethylene biguanide was added to solution (i). In the case of Example 3, following an additional step, carboxymethylcellulose premixed with a portion of water was added to the above obtained solution (i) with stirring. The volume was then corrected with water for injection. The solution was filtered through a 0.2 μm filter. The resulting aqueous ophthalmic solutions of difluprednate (Examples 1-4) had a pH of about 5.0-6.0, an osmolality of about 300 mOsm / kg, and a transmittance of about 99%. The ophthalmic aqueous solutions of Examples 1, 2, and 4 had a viscosity of about 4-5 cps, and the viscosity of the aqueous ophthalmic solution of Example 3 was about 20 cps.

[0093] The physicochemical stability of the formulations was tested upon storage at room temperature (relative humidity 25 / 40%) and 2-8°C for 6 months. Solutions of Examples 1-4 were found to remain clear and free of particles, crystals or precipitates upon storage. Transmittance upon storage was greater than 95%. Assay of difluprednate remained in the range of 95-105% w / v, known and unknown impurities did not increase substantially upon storage, and impurity content remained below the desired specified limits.

[0094] [Comparative Examples 1 to 3] This example shows a comparison of comparative non-Examples 1, 2, and 3 (which do not contain a solubilizer according to the present disclosure) and Examples 5 and 6 (which contain a solubilizer having a mixture of a quaternary ammonium compound and polyethoxylated castor oil) according to the present disclosure. These examples illustrate the surprising effect of using a mixture of a quaternary ammonium compound and polyethoxylated castor oil (Cremophor®), the combination of which acts as an efficient solubilizer of difluprednate in an aqueous vehicle.

[0095] Table 2: Effect of mixture of solubilizers vs. solubilizer alone vs. no solubilizer: [Table 9]

[0096] Benzalkonium chloride is a widely used ingredient as a preservative in ophthalmic formulations. However, the present inventors have found that in the present invention, benzalkonium chloride plays an important role in solubilizing and stabilizing difluprednate molecules in aqueous systems when used together with a non-ionic surfactant such as Cremophor®.

[0097] The inventors have found that the combination of a quaternary ammonium compound, such as benzalkonium chloride, with a non-ionic surfactant, such as polyethoxylated castor oil (Cremophor®), solubilizes the hydrophobic drug-difluprednate in an aqueous vehicle, resulting in the formation of a storage-stable, clear, aqueous solution (Examples 5 and 6) which remains clear and does not undergo precipitation or crystallization of difluprednate upon extended storage (at least 6 months) at room temperature.

[0098] The inventors have observed that the solubilization of difluprednate necessarily requires the use of a quaternary ammonium compound together with the non-ionic surfactant Cremophor®. It has been found that the quaternary ammonium compound together with Cremophor® plays an important role in solubilizing and stabilizing difluprednate molecules in aqueous systems. Primarily, when the two components are present together, the drug is solubilized in the aqueous vehicle.

[0099] However, in the absence of either a quaternary ammonium compound (such as benzalkonium chloride) or polyethoxylated castor oil (Cremophor®), or both, adequate solubilization of difluprednate in aqueous solution did not occur, and the resulting formulations were unstable such that difluprednate crystallized or precipitated (Comparative Examples 1-3).

[0100] [Comparative Examples 4 to 10] These comparative examples examine the effect of various crystal growth inhibitors on the solubilization and stabilization of difluprednate in aqueous solution.

[0101] Aqueous solutions of difluprednate were prepared by replacing polyvinyl alcohol with other crystal growth inhibitors such as hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxyethylstarch, polyvinylpyrrolidone, carboxyvinyl polymers, etc. The physical stability of the solutions was investigated upon storage at room temperature. The details of the quantitative formulations tested along with the stability test results are given in Table 3 below:

[0102] Table 3: Effects of crystal growth inhibitors [Table 10]

[0103] The inventors of the present disclosure have surprisingly discovered that only certain polymers, polyvinyl alcohol or its derivatives, maintain proper solubilization of difluprednate in aqueous solution and act as efficient crystal growth inhibitors to prevent crystallization or precipitation of the drug upon long-term storage at room temperature (Examples 1-6 of the present disclosure). On the other hand, when polymers or surfactants other than polyvinyl alcohol were used (Comparative Examples 4-9), precipitation or crystallization of the drug was found to occur at various time points, as shown in Table 3.

[0104] [Example 7] Preservative Efficacy Testing: The formulation of Example 4 was tested for antimicrobial preservative efficacy according to the Preservative Efficacy Test set forth in the European Pharmacopoeia, 7.0 Edition, section 5.3.1, Pages 505-506, which is incorporated herein by reference in its entirety.

[0105] The results of the bacterial preservative efficacy tests according to the European Pharmacopoeia acceptance criteria A and B are shown in Table 4 below: Table 4: Preservative Effectiveness Test Results: [Table 11]

[0106] The aqueous solution of the present disclosure (Example 4) was found to meet the European Pharmacopoeia's requirements for antimicrobial preservation efficacy criteria A and B, i.e., the required log reduction of bacteria was achieved at 6 hours, 24 hours, and 7 days per criterion A, and at 24 hours, 7 days, and 28 days per criterion B. Antimicrobial preservative effectiveness testing was also performed on separate batches of the aqueous solution that did not contain a biguanide, and it was observed that the antimicrobial preservative effectiveness was inferior to that observed for the batches with a biguanide, with the inclusion of a biguanide, such as polyhexamethylene biguanide, serving to enhance the antimicrobial efficacy of the aqueous solution.

[0107] [Example 8] Effect of different preservatives on antibacterial efficacy These comparative examples test the antimicrobial effectiveness of different preservatives in difluprednate aqueous solution.These examples illustrate the surprising effectiveness of using a preservative mixture of benzalkonium chloride, N-lauroyl sarcosine and boric acid.To establish the inclusion of these components, various compositions are prepared with and without preservatives and preservative mixtures and tested for antimicrobial efficacy test.

[0108] Table 5: Antimicrobial efficacy test (AET) results: [Table 12]

[0109] It was observed that the presence of boric acid in the aqueous solution of the composition helped the formulation to meet the specifications according to the acceptance criteria of the antimicrobial efficacy test defined by the United States Pharmacopoeia. When N-lauroyl sarcosine was used alone as a preservative (Example 2), the batch did not meet the acceptance criteria of the antimicrobial efficacy test defined by the United States Pharmacopoeia and the criteria A and B defined by the European Pharmacopoeia. When both boric acid and benzalkonium chloride were present in the formulation (Examples 3 and 5), the batch complied with the antimicrobial efficacy test according to the United States Pharmacopoeia. The inclusion of N-lauroyl sarcosine (Example 5) helped the formulation to comply with the criteria B of antimicrobial activity according to the European Pharmacopoeia.

[0110] Table 6 below shows the results of antimicrobial efficacy test of the batch containing the mixture of preservatives including benzalkonium chloride, N-lauroyl sarcosine, boric acid and polyhexamethylene biguanide.In addition, glacial acetic acid and EDTA are added to meet the desired physicochemical properties of the formulation.Also, the amount of benzalkonium chloride, boric acid, sodium acetate and glycerin is optimized to meet the target physicochemical properties.

[0111] Table 6: Antimicrobial efficacy test (AET) results: [Table 13]

[0112] Surprisingly, it was found that when a mixture of preservatives including benzalkonium chloride, N-lauroyl sarcosine, boric acid and polyhexamethylene biguanide was used, both batches (Examples 1 and 2) passed the antimicrobial efficacy test criteria according to the Antimicrobial Efficacy Test Criteria B defined in the United States Pharmacopoeia and the European Pharmacopoeia. Thus, the use of a mixture of preservatives helps to enhance the antimicrobial efficacy of the aqueous solution.

[0113] [Example 9] Animal Efficacy Study in a Bovine Serum Albumin-Induced Chronic Uveitis Model - The efficacy of the difluprednate aqueous ophthalmic solution of the present disclosure was tested in a bovine serum albumin-induced chronic uveitis model in NZW rabbits and compared to the commercially available Durezol® formulation.

[0114] Placebo, i.e., formulation vehicle as in Example 1 but without difluprednate. The difluprednate ophthalmic aqueous solution of Example 1 having 0.03% w / v difluprednate. The difluprednate ophthalmic aqueous solution of Example 2 having 0.04% w / v difluprednate. Reference item, Durezol® - Difluprednate (0.05% w / v) ophthalmic emulsion formulation by Alcon.

[0115] The study was carried out on New Zealand White rabbits weighing 3-5 kg. The animals were divided into seven groups, with five animals in each group. The seven groups included - Group 1 - Normal control group Group 2 - Water for injection (WFI) group Group 3 - BSA or bovine serum albumin (disease control) group Group 4 - Placebo group Group 5 - Example 1 group Group 6 - Example 2 group Group 7 - Reference item (Durezol®) group

[0116] On day 0, all animals except the normal control group were anesthetized with ketamine and xylazine by intramuscular route, and one drop of lignocaine was applied to each eye for local anesthesia. On day 0, in groups 3-8, 200 μL of BSA (5%) was injected intravitreally in both eyes, and on day 7, animals were challenged with a marginal ear vein injection of 2.5 mL of BSA (2%). On day 0, in the WFI control group (group 2), 200 μL of sterile WFI was injected intravitreally as above, and on day 7, 2.5 mL of WFI was administered intravenously via the marginal ear vein.

[0117] Placebo, Example 1 solution, Example 2 solution and reference item were administered to each group of animals on day 7 after a 1 hour intravenous challenge with BSA, and thereafter administration continued until day 27 of the study. 50 μL of placebo, Example 1 solution and Example 2 solution were topically instilled twice at 12 hour intervals into both eyes of animals in each group using a micropipette from day 7 to day 27. 50 μL of the reference item were instilled four times at 4 hour intervals into both eyes of animals in each group using a micropipette from day 7 to day 27. Normal control, WFI and BSA (disease control) animals remained untreated. On days 14, 21 and 28, each animal was anesthetized using intramuscular injections of ketamine and xylazine. Eyes were examined for clinical grading using a Zeiss slit lamp. Clinical evaluation of uveitis included assessment of total clinical score (0-10 point scale shown in Table 5) on days 14, 21 and 28. Clinical assessment of uveitis further included assessment of aqueous humor total cell count and total protein on day 28.

[0118] Table 7: Clinical signs and grades of uveitis [Table 14]

[0119] Observations: Observations of total clinical scores (0-10) on days 14, 21 and 28; total cell count and total protein in aqueous humor on day 28 are shown in Table 8 below:

[0120] Table 8: Observations [Table 15]

[0121] It was observed that when instilled twice daily in eyes affected by chronic uveitis, the aqueous difluprednate ophthalmic solution of the present disclosure (Examples 1 and 2) having 0.03% w / v to 0.04% w / v difluprednate showed significant inhibition of total clinical score, total cell count and total protein compared to placebo. In particular, for Example 1 group, whose aqueous solution had 0.03% w / v difluprednate, the mean clinical score was significantly reduced from 7.7 (placebo) to 2.9 on day 21 and from 8.0 (placebo) to 3.4 on day 28. Similarly, for Example 2 group, whose formulation had 0.04% w / v difluprednate, the mean clinical score was significantly reduced from 7.7 (placebo) to 3.5 on day 21 and from 8.0 (placebo) to 3.3 on day 28.

[0122] Total clinical scores, total cell counts and total protein levels were also significantly attenuated by the reference item Durezol® compared to the BSA (disease control) group.

[0123] With twice daily administration of the low concentration (0.03% and 0.04%) aqueous difluprednate ophthalmic solutions of the present disclosure, clinical score values, total cell counts and total protein content of the aqueous humor observed on days 14, 21 and 28 were equal to or better than those observed with the higher concentration 0.05% w / v emulsion formulation Durezol® (commercial reference product) administered four times daily.

[0124] [Example 10] Animal Efficacy Study in Lipopolysaccharide (LPS)-Induced Acute Uveitis Model - The efficacy of the disclosed aqueous difluprednate ophthalmic solution was tested in lipopolysaccharide (LPS) (endotoxin)-induced acute uveitis in female NZW rabbits and compared to the commercially available Duresol® formulation. Various formulations tested included:

[0125] Placebo: formulation vehicle as in Example 1 but without difluprednate. The difluprednate ophthalmic aqueous solution of Example 1 having 0.03% w / v difluprednate. The difluprednate ophthalmic aqueous solution of Example 2 having 0.04% w / v difluprednate. Durezol® difluprednate (0.05% w / v) ophthalmic emulsion formulation (manufactured by Alcon).

[0126] The study was carried out on New Zealand White rabbits weighing 3-5 kg. The animals were divided into seven groups, with five animals in each group. The seven groups included - Group 1 - Normal control group Group 2-Phosphate buffered saline (PBS) group Group 3 - Lipopolysaccharide (LPS disease control) group Group 4 - Placebo group Group 5 - Example 1 group Group 6 - Example 2 group Group 7 - Reference item (Durezol®) group.

[0127] On day 0, all animals except the normal control group were anesthetized with ketamine and xylazine by intramuscular route, and one drop of lignocaine was applied to each eye for local anesthesia. On day 0, in the PBS control group, 20 μL of sterile phosphate buffered saline pH 7.4 was injected intravitreally in both eyes. In groups 3-8, 20 μL of LPS (100 ng) was injected intravitreally in both eyes. One hour after LPS injection, placebo, solutions of Examples 1 and 2, and reference item were administered, where 50 μL of placebo and solutions of Examples 1 and 2 were topically instilled twice at 12-hour intervals in both eyes of animals in each group using a micropipette, while 50 μL of the reference item was injected four times at 4-hour intervals in both eyes of animals in each group using a micropipette. Normal control, PBS, and LPS (disease control) animals remained untreated. 24 hours after LPS injection, each animal was anesthetized with an intramuscular injection of ketamine and xylazine. The eyes were examined for clinical grading using a Zeiss slit lamp.

[0128] Clinical assessment of uveitis included assessment of total clinical score (0-5 scale shown in Table 7 below) on day 1. Clinical assessment of uveitis further included assessment of total aqueous humor cell count and total protein on day 1.

[0129] After clinical scoring, aqueous humor was collected from each animal using a 30-gauge needle attached to an appropriate syringe. Aqueous humor samples were stored at 2–80°C until analysis. Total cell counts and total protein were calculated for each animal.

[0130] Table 9: Clinical signs and grades of uveitis [Table 16]

[0131] Observations: Observations of total clinical score (0-5); total cell count and total protein in aqueous humor on day 1 are shown in Table 10 below:

[0132] Table 10: Observations [Table 17]

[0133] It was observed that when instilled twice daily into eyes affected by acute uveitis, the difluprednate ophthalmic aqueous solutions of the present disclosure (Examples 1 and 2) having 0.03% w / v to 0.04% w / v difluprednate showed significant inhibition of total clinical score, total cell count and total protein compared to placebo. In particular, for the Example 1 group (0.03% w / v difluprednate solution), the mean clinical score was significantly reduced from 3.0 (placebo) to 1.0 on day 1. Similarly, for the Example 2 group (0.04% w / v difluprednate solution), the mean clinical score was significantly reduced from 3.0 (placebo) to 0.7.

[0134] Total clinical score, total cell count and total protein levels were also significantly attenuated by the reference item Durezol® compared to the BSA (disease control) group. Notably, the mean clinical score decreased from 3.0 (placebo) to 0.7 on day 1.

[0135] Clinical score values, total cell counts and total protein content of the aqueous humor observed on day 1 with twice daily administration of the low concentration (0.03% w / v and 0.04% w / v) aqueous difluprednate ophthalmic solutions of the present disclosure were equal to or better than those observed with four times daily administration of the higher strength 0.05% w / v emulsion formulation Durezol® (commercial reference product).

[0136] [Example 11] A randomized, double-blind, parallel-group, multicenter study was conducted to evaluate the efficacy and safety of twice-daily difluprednate ophthalmic solution 0.04% compared with vehicle for the treatment of inflammation and pain associated with ocular surgery.

[0137] In this study, 357 subjects were screened. Of the 357, 325 subjects were in the randomized intention-to-treat (ITT) population, and 32 subjects failed the inclusion / exclusion criteria and were considered screening failures. A total of 26 subjects were randomized but not dosed.

[0138] Of the 299 treated subjects, 154 subjects received at least one dose of the study product and 145 subjects received the reference product. The modified intent-to-treat (mITT) dataset included randomized subjects who underwent cataract surgery, received at least one dose of the investigational drug (IP), and had at least one postoperative efficacy assessment (study: 154 and reference: 144). The per protocol dataset included all mITT subjects who completed the study evaluations at the healing visit at the postoperative day 15 visit without any protocol violations that would have affected the treatment evaluations (study: 123 and reference: 83). A total of 232 subjects completed the study, with 21 subjects in the study arm and 72 subjects in the reference arm discontinuing the study for various reasons.

[0139] Subjects of both genders were enrolled. In the test group, 64 (39.3%) subjects were male and 99 (60.7%) were female. The mean age was 68.4 years. In the reference group, 68 (42.0%) subjects were male and 94 (58.0%) were female, with a mean age of 68.6 years.

[0140] In this study, 240 subjects (73.85%) were Caucasian, 73 (22.5%) were Black or African American, 9 (2.8%) were Asian, and 3 (90.9%) were other. Race was equally distributed between the two treatment groups. Similar trends were seen for ethnicity: Hispanic or Latino, 85 (26.2%) and non-Hispanic or Latino, 239 (73.5%).

[0141] Primary Efficacy Analysis: Proportion of Subjects with Anterior Chamber Cell (ACC) Grade 0 on Day 15 Subjects with an ACC grade of 0 at the day 15 visit or at the last assessment before the day 15 visit (if day 15 was not completed) were considered responders to treatment. Also, if a subject had an ACC score >0 at day 15 or at the last assessment before the day 15 visit (if day 15 was not completed), the subject was considered a failure (or non-responder) in the primary efficacy endpoint analysis. Additionally, subjects who received rescue therapy between the day 0 and day 15 visits (inclusive) were considered treatment failures.

[0142] Thus, considering the mITT population (N=299), the test group recorded 60.4% responders and the reference group recorded 20.8% responders. A statistically significant result in favor of the test drug (p-value<0.0001) indicated that the primary objective was met. A similar trend was seen in the Per Protocol (PP) population (p-value<0.0001).

[0143] Table 11: Observations [Table 18]

[0144] On day 15, more than 50% of subjects were observed to have an anterior chamber cell (ACC) grade of 0.

[0145] Key secondary efficacy endpoints: Proportion of subjects with a visual analog scale (VAS) score of 0 at Day 15 Comparison of the proportion of subjects with a VAS score of 0 (zero) showed statistically significant results (p-value = 0.0006) in favor of the test group versus the reference group for both the intent-to-treat (ITT) and per-protocol (PP) populations. Thus, the key secondary objective of the study was met.

[0146] Table 12: Observations [Table 19]

[0147] Over 90% of subjects were observed to have a pain score of 0 on the visual analog scale at day 15.

[0148] Overview of Treatment-Emergent Adverse Events (TEAEs) There were a total of 508 TEAEs, 317 in the reference group and 191 in the test group. These TEAEs occurred in 87 subjects (56.5%) in the test group and 96 subjects (66.2%) in the reference group. Only 4 subjects (2 in each group) experienced serious TEAEs. None of these were related to the study drug. Twelve subjects (7.8%) in the test group experienced drug-related TEAEs, and 25 subjects (17.2%) in the reference group experienced drug-related TEAEs. Study drug was permanently discontinued in 24 subjects (8.0%) due to a TEAE. A total of 63 subjects received concomitant medications as treatment for the TEAE. TEAEs resolved in 157 subjects (52.5%), whereas in 45 subjects (15.1%), the event was ongoing at the end of the study.

[0149] Table 13: Observations [Table 20]

[0150] The inventors have found that an aqueous difluprednate ophthalmic solution of the present disclosure having 0.04% w / v difluprednate, when administered twice daily to a subject's eye to treat pain and inflammation following ocular surgery, led to the subject having an anterior chamber cell (ACC) grade of 0 and a pain score of 0 on the visual analog scale (VAS), and the subject did not receive rescue treatment.

Claims

1. 1. Use of an aqueous solution containing difluprednate as the sole active ingredient in a concentration of 0.02-0.04% weight / volume in an aqueous vehicle in the manufacture of a medicament for a method of reducing inflammation in the anterior chamber of the eye, comprising: wherein the solution is oil-free; The method comprises administering the medicament twice daily to the eye of a subject who has undergone ophthalmic surgery; wherein the subject has not received rescue therapy, and wherein after the treatment, the subject has an anterior chamber cell (ACC) grade of 0 and a visual analog scale (VAS) pain score of 0 after ophthalmic surgery 15 days after administration; use.

2. The use according to claim 1, wherein the ophthalmic surgery is cataract surgery.

3. 1. Use of an aqueous solution containing difluprednate as the sole active ingredient in a concentration of 0.02-0.04% weight / volume in an aqueous vehicle in the manufacture of a medicament for a method of achieving anterior chamber cell count (ACC) grade 0 in a subject in need thereof, comprising: wherein the solution is oil-free; The method comprises administering the medicament to the eye of the subject twice daily for 7 to 21 days; wherein the subject has not received rescue therapy. use.

4. The use according to claim 3, wherein the subject in need of achieving an ACC grade 0 has undergone ophthalmic surgery.

5. 1. Use of an aqueous solution containing difluprednate as the sole active ingredient in a concentration of 0.02-0.04% weight / volume in an aqueous vehicle in the manufacture of a medicament for a method of achieving a pain score of 0 on a visual analogue scale (VAS) in a subject in need thereof, comprising: wherein the solution is oil-free; The method comprises administering the medicament to the eye of the subject twice daily for 7 to 21 days; wherein the subject has not received rescue therapy. use.

6. The use according to claim 5, wherein the subject in need of achieving a pain score of 0 on a VAS has undergone ophthalmic surgery.

7. 1. Use of an aqueous solution containing difluprednate as the only active ingredient in a concentration of 0.02-0.04% weight / volume in an aqueous vehicle in the manufacture of a medicament for a method of treating an ocular inflammatory disorder, comprising: wherein the solution is oil-free; The method comprises administering the medicament twice daily for 14 days to the eye of a patient in need thereof; wherein the patient does not receive rescue treatment, and after the treatment, the patient has an anterior chamber cell grade of 0. use.

8. 8. The use according to claim 7, wherein the ocular inflammatory disorder is pain and inflammation associated with ocular surgery.

9. The use according to claim 8, wherein the ophthalmic surgery is cataract surgery.

10. The use according to claim 7, wherein the difluprednate is present in a concentration of 0.04% weight / volume.

11. 8. The use of claim 7, wherein the method results in a pain score of 0 on a visual analogue scale 15 days after ophthalmic surgery.

12. The use according to claim 11, wherein the pain score on a visual analogue scale is assessed based on the Ocular Pain and Discomfort Scoring from 0 to 100.

13. 1. An aqueous solution comprising difluprednate as the sole active ingredient in a concentration of 0.02 to 0.04% weight / volume in an aqueous vehicle for use in reducing inflammation in the anterior chamber of the eye in a subject who has undergone ophthalmic surgery, wherein the solution is oil-free; wherein the solution is administered twice daily; wherein the subject has not received rescue therapy, and wherein after said treatment, said subject has an anterior chamber cell count (ACC) grade of 0 and a visual analog scale (VAS) pain score of 0 after ophthalmic surgery 15 days after administration; Aqueous solution.

14. 14. The aqueous solution for use in reducing inflammation in the anterior chamber of the eye of claim 13, wherein said ophthalmic surgery is cataract surgery.

15. 1. An aqueous solution comprising difluprednate as the sole active ingredient in a concentration of 0.02-0.04% weight / volume in an aqueous vehicle for use in achieving anterior chamber cell count (ACC) grade 0 in a subject in need thereof, wherein the solution is oil-free; wherein the solution is administered twice daily for 7 to 21 days; and wherein the subject is not receiving rescue treatment.

16. 16. The aqueous solution for use in reducing inflammation in the anterior chamber of the eye according to claim 15, wherein the subject in need of achieving an ACC grade 0 has undergone ophthalmic surgery.

17. 1. An aqueous solution comprising difluprednate as the sole active ingredient in a concentration of 0.02-0.04% weight / volume in an aqueous vehicle for use in achieving a pain score of 0 on a visual analog scale (VAS) in a subject in need thereof, comprising: wherein the solution is oil-free; wherein the solution is administered twice daily for 7 to 21 days; and wherein the subject is not receiving rescue treatment.

18. 20. The aqueous solution for use in reducing inflammation in the anterior chamber of the eye of claim 17, wherein the subject has had ophthalmic surgery.

19. 1. An aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02-0.04% w / v in an aqueous vehicle for use in treating an inflammatory disorder of the eye, wherein said solution is oil-free, and wherein said solution is administered twice daily for 14 days, wherein said patient is not receiving rescue therapy, and wherein said patient has an anterior chamber cell grade of 0 following said treatment.

20. 20. The aqueous solution for use in treating an ocular inflammatory disorder of claim 19, wherein the ocular inflammatory disorder is pain and inflammation associated with ocular surgery.

21. 21. The aqueous solution for use in treating an ocular inflammatory disorder according to claim 20, wherein the ophthalmic surgery is cataract surgery.

22. 20. The aqueous solution for use in treating an ocular inflammatory disorder according to claim 19, wherein the difluprednate is present in a concentration of 0.04% weight / volume.

23. 20. The aqueous solution for use in the treatment of an ocular inflammatory disorder of claim 19, wherein the treatment results in a pain score of 0 on a visual analog scale 15 days after ocular surgery.

24. 24. The aqueous solution for use in the treatment of an ocular inflammatory disorder of claim 23, wherein the pain score on a visual analogue scale is assessed based on an ocular pain and discomfort scoring scale of 0 to 100.